Baxter to sell its BioPharma Solutions Business to Advent International and Warburg Pincus for US $4.25billion
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation